Foliglurax Enters Phase II Trial for Treatment of Parkinson's Patients

News   Jul 10, 2017 | Original Story from Prexton Therapeutics

 
Prexton Therapeutic's Parkinson's Drug Candidate, Foliglurax, Enters Phase II Trial
 
 
 

RELATED ARTICLES

Avacta Group plc announces successful outcome of “Gene Delivery” collaboration with FIT Biotech

News

Sustained production of Affimer drugs by muscle tissue in vivo could lead to major patient and commercial benefits.

READ MORE

New Chemistry to Make Smart Drugs Smarter

News

A method to activate targeted drugs, or smart drugs, only at the selected site of action, an approach that improves the drug’s therapeutic effect and minimizes side effects, has been developed in a study led by Georgia State University.

READ MORE

Understanding Lung Cancer Cell Networks Helps Create Drug Treatments

News

A team of scientists has identified networks inside lung cancer cells that will help understand this cancer and fight it with drug treatments.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Drug Discovery Neuroscience

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE